ClinVar Miner

Submissions for variant NM_000051.3(ATM):c.7271T>G (p.Val2424Gly) (rs28904921)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 20
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000212060 SCV000149153 pathogenic not provided 2020-02-13 criteria provided, single submitter clinical testing Case-control studies suggest this variant is associated with breast cancer and confers a higher risk than other ATM variants (Stankovic 1998, Chenevix-Trench 2002, Bernstein 2006, Goldgar 2011, van Os 2016, Southey 2016, Thompson 2016, Decker 2017); Published functional studies demonstrate a damaging effect: cells heterozygous for this variant demonstrate radiosensitivity and decreased kinase activity (Stewart 2001, Chenevix-Trench 2002, Barone 2009, Mitui 2009, Taylor 2014); Observed in the heterozygous state in individuals with ATM-related cancers (Huang 2015, Hart 2016, Southey 2016, Thompson 2016, Decker 2017); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26898890, 26506520, 27595995, 28580595, 27913932, 28452373, 25186627, 29915382, 30549301, 8755918, 16958054, 21787400, 17001622, 24733792, 15928302, 9463314, 24763289, 18634022, 9288106, 22529920, 19781682, 24088041, 11382771, 26786923, 19431188, 26662178, 11830610, 26633545, 26985847, 25980754, 27273131, 14871810, 27528516, 26681312, 28779002, 28454591, 27988859, 28643015, 28840378, 28691344, 29034753, 27798748, 28821472, 28390840, 28439798, 29719442, 29271107, 29665859, 29661970, 29422015, 29341116, 29555025, 27084275, 29506079, 25040471, 18575927, 30197789, 27978560, 31447099)
Ambry Genetics RCV000115244 SCV000172910 pathogenic Hereditary cancer-predisposing syndrome 2018-06-13 criteria provided, single submitter clinical testing The p.V2424G pathogenic mutation (also known as c.7271T>G), located in coding exon 48 of the ATM gene, results from a T to G substitution at nucleotide position 7271. The valine at codon 2424 is replaced by glycine, an amino acid with dissimilar properties. This alteration has been reported in individuals with ataxia-telangiectasia (AT) (McConville CM et al. Am. J. Hum. Genet. 1996 Aug;59:320-30; Stankovic T et al. Am. J. Hum. Genet. 1998 Feb;62:334-45; Marelli C et al. Hum. Mutat. 2016 Dec;37:1340-1353), colorectal cancer (Pearlman R et al. JAMA Oncol. 2017 Apr;3:464-471) as well as individuals with personal history of breast cancer (Kurian AW et al. J. Clin. Oncol. 2014 Jul;32:2001-9; Tung N et al. Cancer. 2015 Jan;121:25-33; Southey MC et al. J. Med. Genet. 2016 12;53:800-811; Susswein LR et al. Genet. Med. 2016 08;18:823-32; Moran O et al. Breast Cancer Res. Treat. 2017 01;161:135-142; Decker B et al. J. Med. Genet. 2017 Nov;54:732-741). This alteration impacts an evolutionarily conserved residue in the 3' FAT functional domain of the ATM protein and has been shown to act in a dominant-negative manner (Tavtigian S et al. Am. J. Hum. Genet. 2009 Oct;85:427-46; Waddell N et al. Genes Chromosomes Cancer. 2006 Dec;45:1169-81). In a large case-control study the p.V2424G pathogenic mutation was shown to be associated with a significantly increased risk for breast cancer (OR=11.0, 95% CI 1.42 to 85.7) (Southey MC et al. J. Med. Genet. 2016 12;53:800-811). Pedigree analyses of numerous p.V2424G-carrier families with multiple cases of breast cancer have produced lifetime cumulative breast cancer risk estimates ranging from 52% to 69% for this specific allele (Stankovic T et al. Am. J. Hum. Genet. 1998 Feb;62:334-45; Chenevix-Trench G et al. J. Natl. Cancer Inst. 2002 Feb;94:205-15; Bernstein JL et al. Hum. Mutat. 2006 Nov;27:1122-8; Goldgar D et al. Breast Cancer Res. 2011 Jul;13:R73). Functional assays show that this mutation retains some residual kinase activity and has been seen in some patients with a milder AT phenotype (Thompson D et al. J. Natl. Cancer Inst. 2005 Jun;97:813-22; Barone G et al. Hum. Mutat. 2009 Aug;30:1222-30). Based on the majority of available evidence to date, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000168223 SCV000218891 pathogenic Ataxia-telangiectasia syndrome 2020-11-01 criteria provided, single submitter clinical testing This sequence change replaces valine with glycine at codon 2424 of the ATM protein (p.Val2424Gly). The valine residue is highly conserved and there is a moderate physicochemical difference between valine and glycine. This variant is present in population databases (rs28904921, ExAC 0.005%). This variant has been reported in individuals affected with autosomal recessive ataxia-telangiectasia (PMID: 9463314, 8755918), and has been observed to segregate with disease in two families (PMID: 18575927, 9463314). It has also been reported in numerous individuals affected with breast cancer (PMID: 11830610, 19781682, 16958054, 21787400, 24733792), and an individual with gastric cancer (PMID: 26506520). ClinVar contains an entry for this variant (Variation ID: 3023). In large multi-center case-control and family-based studies, this variant was shown to be strongly associated with breast cancer risk among Caucasian women (OR=8.0-11.0, 95% CI 1.42-85.7, p<0.01) (PMID: 27595995, 21787400). In two smaller case-control studies, the cumulative risk for breast cancer at age 70 years was determined to be 34-69% (PMID: 11830610, 16958054, 17001622). Experimental studies have shown that this missense change disrupts ATM kinase activity (PMID: 11382771, 11830610, 18634022, 19431188). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV000168223 SCV000245452 pathogenic Ataxia-telangiectasia syndrome 2014-09-22 criteria provided, single submitter clinical testing This variant has been previously reported as disease-causing and was found twice in our laboratory in affected individuals who carried second pathogenic variants in the gene.
Genetic Services Laboratory, University of Chicago RCV000168223 SCV000246619 pathogenic Ataxia-telangiectasia syndrome 2014-06-27 criteria provided, single submitter clinical testing
Color Health, Inc RCV000115244 SCV000292134 pathogenic Hereditary cancer-predisposing syndrome 2020-09-25 criteria provided, single submitter clinical testing This missense variant replaces valine with glycine at codon 2424 in the FAT domain of the ATM protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant results in a significantly decreased ATM kinase activity (PMID: 11382771, 11830610, 18634022). This variant has been reported in over 50 individuals affected with breast cancer (PMID: 9463314, 11830610, 16958054, 21787400, 24733792, 25186627, 26681312, 27595995, 27798748, 28779002). A large breast cancer case-control study reported this variant to confer increased risk of the disease (OR 11.6, 95% CI 1.50 to 89.9, p-value = 0.0012; PMID: 27595995), comparable to BRCA1 and BRCA2 pathogenic mutations (PMID: 11830610, 16958054, 26662178). This variant has been observed in multiple families affected with attenuated ataxia-telangiectasia in homozygous state or compound heterozygous state with pathogenic truncation variants (PMID: 8755918, 9463314, 18575927, 27528516). This variant has been identified in 12/282354 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic.
Counsyl RCV000168223 SCV000486203 likely pathogenic Ataxia-telangiectasia syndrome 2016-05-16 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000168223 SCV000602560 pathogenic Ataxia-telangiectasia syndrome 2019-05-04 criteria provided, single submitter clinical testing The ATM c.7271T>G; p.Val2424Gly variant (rs28904921) is associated with an increased risk for breast and other cancers (Goldgar 2011, Kurian 2014, Stankovic 1998, Tavtigian 2009, Yurgelun 2015). It is also reported in association with autosomal recessive ataxia telangiectasia in both a homozygous state and in a compound heterozygous state with other ATM variants. (McConville 1996, Stankovic 1998). The p.Val2424Gly variant does not alter the abundance of the ATM protein but several studies have shown that it impairs ATM kinase activity and DNA repair (Barone 2009, Mitui 2009, Stankovic 1998). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 3023). It is found in the general population with an overall allele frequency of 0.004% (12/282354 alleles) in the Genome Aggregation Database. The valine at codon 2424 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Based on available information, this variant is considered to be pathogenic. REFERENCES Barone G et al. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat. 2009 Aug;30(8):1222-1230. Goldgar DE et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011 Jul 25;13(4):R73. Kurian AW et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol. 2014 Jul 1;32(19):2001-2009. McConville CM et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet. 1996 Aug;59(2):320-30 Mitui M et al. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat. 2009 Jan;30(1):12-21 Stankovic T et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet. 1998 Feb;62(2):334-345. Tavtigian SV et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009 Oct;85(4):427-446. Yurgelun MB et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology. 2015 Sep;149(3):604-13.e20.
Fulgent Genetics,Fulgent Genetics RCV000515429 SCV000611166 pathogenic Familial cancer of breast; Ataxia-telangiectasia syndrome 2017-05-18 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000168223 SCV000694344 pathogenic Ataxia-telangiectasia syndrome 2017-06-05 criteria provided, single submitter clinical testing
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine RCV000709707 SCV000839881 pathogenic Familial cancer of breast 2017-04-03 criteria provided, single submitter clinical testing This c.7271T>G (p.Val2424Gly) has previously been reported in compound heterozygous and homozygous patients with ataxia telangiectasia [PMID 8755918, 9463314, 18575927]. Functional assays showed that the variant does not affect the level of ATM protein but does reduce the level of kinase activity [PMID 18634022]. This variant has seen observed at the heterozygous state in at least 24 patients from two cohorts of breast cancer patients [PMID 19781682, 21787400]. Statistical analysis in one cohort estimated the risk factor for breast cancer to be 8.0 for carriers of this variant compared to 4.4 for families carriers of other pathogenic variants. This variant was observed in 3 Europeans (Non Finnish) at the heterozygous state in the ExAC population database ( This variant is highly conserved in mammals. While not validated for clinical use, computer-based algorithms (SIFT and Polyphen-2) predict this p.Val2424Gly change to be deleterious. It is thus interpreted as a pathogenic variant.
Mayo Clinic Laboratories, Mayo Clinic RCV000212060 SCV001713585 pathogenic not provided 2020-10-07 criteria provided, single submitter clinical testing PS3, PS4, PM2, PM3, PP1, PP3, PP5
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000212060 SCV001762230 pathogenic not provided 2021-06-17 criteria provided, single submitter clinical testing
OMIM RCV000003159 SCV000023317 pathogenic Ataxia-telangiectasia variant 2006-11-01 no assertion criteria provided literature only
OMIM RCV000003160 SCV000023318 pathogenic T-cell prolymphocytic leukemia 2006-11-01 no assertion criteria provided literature only
OMIM RCV000003161 SCV000023319 risk factor Breast cancer, susceptibility to 2006-11-01 no assertion criteria provided literature only
CSER _CC_NCGL, University of Washington RCV000417259 SCV000503552 pathogenic Breast neoplasm 2016-08-01 no assertion criteria provided research Found in a male patient having exome sequencing for an unrelated indication. No known history of breast cancer. Family history of a mother with bilateral breast cancer diagnosed at age 88 and 93.
GenomeConnect, ClinGen RCV000212060 SCV000986703 not provided not provided no assertion provided phenotyping only Variant interpretted as pathogenic and reported on 11/30/2017 by GTR ID Trillium Health Partners. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000212060 SCV001554125 pathogenic not provided no assertion criteria provided clinical testing The ATM p.Val2424Gly variant was identified in 20 of 14588 proband chromosomes (frequency: 0.0013) from individuals or families with contralateral and bilateral breast cancers (Bernstein 2003, Bernstein 2010, Chenevix-Trench 2002, Goldgar 2011, Waddell 2006). The variant was also identified in dbSNP (ID: rs28904921) as “with pathogenic allele”, in the ClinVar database (as pathogenic by GeneDx, Ambry Genetics, Invitae, and 8 additional clinical laboratories, and as likely pathogenic by Counsyl), in the Cosmic database (2x as pathogenic), and in the LOVD 3.0 database (6x as pathogenic). The variant was not identified in the COGR or in the MutDB databases. The variant was also identified in control databases including the NHLBI GO Exome Sequencing Project in 1 of 8596 European American alleles and in 14 of 276788 chromosomes at a frequency of 0.00005 in the Genome Aggregation Database (Feb 27, 2017). It was observed in the following populations: Latino in 1 of 34412 chromosomes (freq: 0.00003), and European Non-Finnish in 13 of 126414 chromosomes (freq: 0.0001); it was not observed in the African, Other, Ashkenazi Jewish, East Asian, Finnish, or South Asian populations. In vivo analyses of cell lines established from individuals heterozygous for the c.7271T>G variant suggest that this ATM variant acts in a dominant negative manner so that the wild-type enzyme is unable to function normally in the presence of the mutant protein. Results reveal that the mutant ATM protein from the c.7271T>G heterozygotes is stable but intrinsically defective as a kinase. It appears that, in cells with these mutant ATM alleles, p53 phosphorylation and stabilization are reduced, which presumably decreases the effectiveness of the cell cycle checkpoint (Chenevix-Trench 2002). In another study, the c.7271T>G variant was genotyped and modified segregation analysis was used to estimate the breast cancer penetrance. Women carrying the variant, ATM c.7271T>G demonstrate a significantly increased risk of breast cancer with a penetrance that appears similar to that conferred by germline mutations in BRCA2. Separate analyses of the 15 families carrying the ATM c.7271T>G variant found that this variant increased breast cancer risk by a factor of 8.0 compared with 4.4 for families with other ATM variants (Goldgar 2011). Another study confirmed that the p.Val2424Gly variant confers a moderate risk of breast cancer, with an estimated hazard ratio of 6.1. Furthermore, the study revealed that the V2424 allele was found across seven vertebrate sequences. To elucidate the molecular effects of the ATM 7271T>G variant, a study carried out expression profiling and demonstrated that the ATM 7271T>G variant acts largely as a dominant negative causing differences in expression profiles of many genes (Waddell 2006). The p.Val2424 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and 4 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing. However, this information is not predictive enough to assume pathogenicity. In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Human Genetics - Radboudumc,Radboudumc RCV000212060 SCV001954117 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.